ライフサイエンスコーパス: drug-associated

1 high titers of anti-MPO antibodies are often drug-associated.

2 DNA variants appearing to predispose to drug-associated "acquired" long-QT syndrome (aLQTS) have

3 d a surge in unintentional deaths, increased drug-associated acute coronary syndrome, and endocarditi

4 s study was to characterize the pharmacogene-drug-associated ADR reporting landscape from a national

5 otal of 12 patients (36%) suffered grade 3-4 drug associated adverse event (AE); no grade 5 AE were r

6 ic allows detection of potential vaccine- or drug-associated adverse events without prespecifying the

7 Because of historically high rates of drug-associated adverse events, warfarin remains underpr

8 d thrombocytopenia (6%) were the most common drug-associated adverse events.

9 interrupted in 9 patients (1.5%) because of drug-associated adverse events.

10 We uncover drug-associated alterations in microbiota-derived N-acyl

11 Drug-associated anaphylaxis is a common condition with s

12 ile most drugs reported that the majority of drug-associated anaphylaxis reports occurred within 2.5

13 the strength of their signal detections with drug-associated anaphylaxis.

14 acovigilance database to identify reports of drug-associated anaphylaxis.

15 asculitis may quickly develop a superimposed drug-associated ANCA-positive vasculitis.

16 ions, such as nonsteroidal anti-inflammatory drug-associated angioedema and serum sickness-like react

17 Drug-associated B-cell activation may contribute to this

18 expressed in the VTA are capable of altering drug-associated behavior, our current results suggest th

19 ing novel cocaine gene targets that regulate drug-associated behaviors.

20 reward circuitry that can lead to persistent drug-associated behaviors.

21 cocaine and encodes information that drives drug-associated behaviors.

22 le of RGS4 in nonsteroidal anti-inflammatory drug-associated bronchoconstriction by challenging aspir

23 Here we report the new onset of severe drug-associated colitis with surgical complications in a

24 An increase in preference for the drug-associated compartment is observed after a single e

25 drug-seeking behavior that was maintained by drug-associated conditioned reinforcers and assessed usi

26 ions in cocaine seeking under the control of drug-associated conditioned reinforcers.

27 mote cocaine-seeking behavior in response to drug-associated conditioned stimuli (CS) and share dense

28 Pavlovian drug-associated conditioned stimuli exert a major influe

29 that DR inputs to CA1 augment recall of the drug-associated context and drug seeking via 5-HT(1B) re

30 g, we demonstrate enhanced representation of drug-associated context and persistent inhibitory signal

31 at persistent PL inhibitory signaling in the drug-associated context during motivational conflict may

32 On the test day, rats exposed to the drug-associated context, after extinction in a different

33 a significant increase in preference for the drug-associated context, with a linear trend for increas

34 Drug-associated contexts and cues activate ensembles of

35 re-activation of these neuronal ensembles by drug-associated contexts during abstinence provoked drug

36 sociation between drug rewarding effects and drug-associated contexts has remained unclear.

37 riming), discrete cues, discriminative cues, drug-associated contexts, different forms of stress, or

38 tially contributing to reinforce memories of drug-associated contexts.

39 s examining the potential reconsolidation of drug-associated contextual memories, rats were given a s

40 a renewal procedure, the authors report that drug-associated contextual stimuli play a critical role

41 derlying relapse to drug seeking elicited by drug-associated contextual stimuli.

42 iii) a test that offers a choice between the drug-associated cue and a neutral cue.

43 dependent increase in their response for the drug-associated cue as compared to mice that self-admini

44 entral tegmental area (VTA) are critical for drug-associated cue learning and drug reinforcement proc

45 Discriminative stimuli (DSs) are one type of drug-associated cue that signal drug availability (DS+)

46 (CPP) or less time (CPA) in proximity to the drug-associated cue.

47 VTA dopamine neurons blocked the ability of drug-associated cues (but not a cocaine prime) to reinst

48 Meanwhile, drug-associated cues (conditioned stimulus [CS]) also ga

49 mental drug-seeking behavior that depends on drug-associated cues acting as conditioned reinforcers.

50 tolerance develops as a learned response to drug-associated cues and is thus a dynamic effect modula

51 ratio schedule and reinstatement induced by drug-associated cues and stress.

52 tablished as associations are formed between drug-associated cues and the conditioned responses they

53 To disentangle the interaction between drug-associated cues and the consummatory and appetitive

54 Breaking the contingencies between drug-associated cues and the delivery of the reward duri

55 However, drug-associated cues are also known to provoke striatal

56 Drug-associated cues are believed to be important mediat

57 Drug-associated cues can acquire powerful motivational c

58 ning addictive behaviors, as presentation of drug-associated cues can elicit drug seeking and relapse

59 g abuse; however, it remains unclear whether drug-associated cues can elicit the emotional withdrawal

60 Indeed, exposure to the salient drug-associated cues can lead to drug cravings and drug

61 Here, Wheeler and colleagues show that drug-associated cues come to activate neural representat

62 Attentional bias to drug-associated cues correlates with extent of current u

63 from context, conditioned stimuli, and other drug-associated cues during cocaine self-administration

64 Drug-associated cues elicit conditioned responses in hum

65 Drug-associated cues have profound effects on an addict'

66 ed that the PL-NAcC pathway was recruited by drug-associated cues in a dopamine-dependent manner to d

67 e and reduces craving and anxiety induced by drug-associated cues in abstinent individuals with heroi

68 drug-seeking, and exposure to the drug or to drug-associated cues leads to relapse, even after long p

69 uggest that LTCC blockade during exposure to drug-associated cues may cause unlearning of the increas

70 e by drug-paired cues.SIGNIFICANCE STATEMENT Drug-associated cues precipitate relapse, which is corre

71 xcitatory dHPC neurons during re-exposure to drug-associated cues significantly attenuates cue-induce

72 ty to addiction involves robust memories for drug-associated cues that are difficult to extinguish.

73 and relapse can be triggered by exposure to drug-associated cues that induce drug craving.

74 prefrontal cortex that are thought to allow drug-associated cues to drive compulsive drug seeking an

75 t aspect of drug addiction is the ability of drug-associated cues to elicit craving and facilitate re

76 method to reduce the motivational impact of drug-associated cues to prevent relapse.

77 powerful and sometimes surprising ways, and drug-associated cues trigger relapse to drug seeking in

78 ute to the increased motivational valence of drug-associated cues triggering relapse.

79 evealing a bottleneck in brain processing of drug-associated cues where therapeutic interventions cou

80 t glutamatergic responses to drugs of abuse, drug-associated cues, and stressors.

81 g seeking becomes habitual and controlled by drug-associated cues, and the neural locus of control ov

82 Relapse is often triggered by re-exposure to drug-associated cues, and though the neural substrates r

83 oms including enhanced incentive salience of drug-associated cues, but also a negative affective stat

84 hat in the absence of conscious awareness of drug-associated cues, cocaine and alcohol activate only

85 Drug use is provoked by the presentation of drug-associated cues, even following long periods of abs

86 is frequently triggered by an encounter with drug-associated cues, including the drug itself.

87 cute exposure to the self-administered drug, drug-associated cues, or stress.

88 to drug seeking can be caused by exposure to drug-associated cues, provoking drug craving even after

89 ase where relapse is elicited by exposure to drug-associated cues, the drug itself, or stress.

90 aviour that depends upon the presentation of drug-associated cues, without having any intrinsic, prim

91 that are selectively activated by drugs and drug-associated cues.

92 cessive attribution of incentive salience to drug-associated cues.

93 ute to the attribution of incentive value to drug-associated cues.

94 aptive behavior elicited by fear-related and drug-associated cues.

95 aptive behavior elicited by fear-related and drug-associated cues.

96 cue-induced reinstatement in the absence of drug-associated cues.

97 ceptibility, and relapse can be triggered by drug-associated cues.

98 Relapse to drug use can be initiated by drug-associated cues.

99 apse to drug seeking, and brain responses to drug-associated cues.

100 l immune-related adverse events and consider drug-associated dermatomyositis in the differential diag

101 hese patients, yet a detailed examination of drug-associated effects on cardiovascular structure, pro

102 In rodents, exposure to a drug-associated environment elicits conditioned psychomo

103 he prior history of morphine exposure in the drug-associated environment, since alterations of AMPAR

104 of context-drug memories on re-exposure to a drug-associated environment.

105 ulnerability to relapse that are elicited by drug-associated environmental stimuli.

106 nisms that mediate the effects of real-world drug-associated environments on drug taking behavior und

107 with high titers of anti-MPO antibodies are drug-associated, especially following exposure to hydral

108 Recognition of a drug-associated etiology in a patient with TTP-HUS is cr

109 DDI is based on the 65 different drug-associated events, which is present in the drug ban

110 ecision making may also strongly depend upon drug-associated expectations.

111 of behavioral interventions and US Food and Drug Associated (FDA)-approved pharmacotherapy for tobac

112 In this cohort study, in silico analysis of drug-associated gene expression signatures identified po

113 etwork propagation framework integrated with drug-associated gene signatures to identify potential im

114 rse interaction drugs, drug primary targets, drug-associated genes, and proteins directly interacting

115 richment of cancer signaling pathways across drug-associated genes, gene expression, mutation and cop

116 In this overview, we discuss specific drug-associated hemostatic complications, the already kn

117 of malate dehydrogenase displayed prominent drug-associated increases in expression compared with un

118 rization (MSBMF) method to predict promising drug-associated indications for existing and novel drugs

119 Identification of potential drug-associated indications is critical for either appro

120 i-layer networks (OMC3) to predict potential drug-associated indications, respectively.

121 ory processes and may play critical roles in drug-associated learning and addiction.

122 at disrupting ASIC1A in the NAc would reduce drug-associated learning and memory.

123 f torsades de pointes (TdP) in patients with drug-associated long QT syndrome (LQTS).

124 was a case-control study of 123 adults with drug-associated LQTS.

125 circuitry, which underlies the formation of drug-associated memories and addictive behavior.

126 Drug-associated memories are susceptible to long-term di

127 anol experience may promote the formation of drug-associated memories by enhancing synaptic plasticit

128 Targeted weakening of drug-associated memories has been shown to reduce relaps

129 nomenon that correlates with the strength of drug-associated memories in vivo.

130 Retrieval of drug-associated memories is critical for maintaining add

131 Contextual drug-associated memories precipitate craving and relapse

132 enetic mechanism, nucleosome remodelling, in drug-associated memories remains largely unexplored.

133 Thus, drug-associated memories seem to be actively maintained

134 g to the formation and persistence of strong drug-associated memories that lead to craving and relaps

135 ddiction, and the dopamine signal influences drug-associated memories that perpetuate drug use.

136 evention therapies attempt to interfere with drug-associated memories, but are often hindered by unin

137 ucleus accumbens (NAc) is essential to these drug-associated memories, but underlying mechanisms are

138 ocaine conditioned place preference to model drug-associated memories, we find that cocaine drives re

139 ic potentiation, thus, likely contributed to drug-associated memories.

140 re also necessary for the reconsolidation of drug-associated memories.

141 e of the cellular substrates of long-lasting drug-associated memories.

142 a memory reactivation session disrupted the drug-associated memory and abolished subsequent instrume

143 s and points to the possibility of targeting drug-associated memory in the hippocampus.

144 neural circuitry that mediates expression of drug-associated memory is therefore of crucial importanc

145 T(1B) antagonism alone transiently decreased drug-associated memory performance when given prior to a

146 evidence implicates epigenetic mechanisms in drug-associated memory processes.

147 blockade could induce long-term deficits in drug-associated memory retrieval by reducing neuronal ex

148 y of dorsal hippocampus (dHipp) beta-ARs for drug-associated memory retrieval.

149 he VTA may be important for the formation of drug-associated memory.

150 d triggers a behavioral response driven by a drug-associated memory.

151 treatment of nonsteroidal anti-inflammatory drug-associated mucosal injury.

152 ADE-specific ontologies, including ODNAE for drug-associated neuropathy-inducing AEs and OCVDAE for c

153 ias as isoimmune, autoimmune (including some drug-associated neutropenias), and idiopathic (cases pos

154 ed receptor models that require formation of drug-associated nonconducting states with high affinity

155 and habitual drug seeking, the influence of drug-associated Pavlovian-conditioned stimuli on drug se

156 bular injury strongly suggest a mechanism of drug-associated podocyte and tubular toxicity.

157 Drug-associated sensory cues increase motivation for dru

158 32 patients with first-line antituberculosis drug-associated severe cutaneous adverse reaction (81% H

159 No drug-associated side effects were observed.

160 bling IFN-alpha therapy continuation without drug-associated skin eruptions.

161 Drug-associated stimuli (cues) can usurp potent control

162 ring the development of addiction in humans, drug-associated stimuli acquire increasingly stronger in

163 driven primarily by the interaction between drug-associated stimuli and drug effects.

164 Drug seeking under the control of drug-associated stimuli and its reinstatement after exti

165 nding nature of addiction, as re-exposure to drug-associated stimuli can reinstate drug-seeking and -

166 rincipal role for the NAc in the response to drug-associated stimuli has been well documented.

167 locus in mediating the effects of previously drug-associated stimuli on subsequent drug-seeking behav

168 an established role in encoding the value of drug-associated stimuli, and dopamine release into the N

169 , combined with enhanced excitatory drive by drug-associated stimuli, contributes to the two cardinal

170 ein signaling in the PFC focuses behavior on drug-associated stimuli, while dysregulated PFC-accumben

171 elapse often precipitated by the presence of drug-associated stimuli.

172 ence of excitatory drive that is elicited by drug-associated stimuli.

173 the sensitivity of brain reward circuits to drug-associated stimuli.

174 ility to extinguish conditioned responses to drug-associated stimuli.

175 ed conditioned reinforcing properties of the drug-associated stimulus and thus its impact on the lear

176 gical and behavioral treatments that disrupt drug-associated stimulus memories could be beneficial in

177 s suggesting that rats avoided intake of the drug-associated taste cue because the value of the taste

178 liver disease/nonalcoholic steatohepatitis, drug-associated toxicities, and other metabolic/genetic

179 patients (12.5%) were removed from study for drug-associated toxicity (five thromboembolic events, on

180 he treatment of uveitis has been linked with drug-associated toxicity and adverse events (AEs).

181 anagement of chronic infection by decreasing drug-associated toxicity and improving quality of life w

182 ing genomic and transcriptomic mechanisms in drug-associated transcriptional cell states.

183 Here, we explore the function of a drug-associated, transcriptionally repressive transcript

184 od treatment is well-tolerated with no study drug associated treatment discontinuations.

185 Quinine is a common cause of drug-associated TTP-HUS and can cause death and chronic

186 t of the most and the most recent reports of drug-associated TTP-HUS are discussed: mitomycin C, cycl

187 A systematic analysis of reports of drug-associated TTP-HUS will be required to better under

188 cause of the high mortality and morbidity of drug-associated TTP-HUS.

189 inemia is a key contributor to antipsychotic drug-associated weight gain and metabolic deterioration.

190 in antimetastatic activity without producing drug-associated weight loss as observed with systemic ad

191 id (TA) is a non-steroidal anti-inflammatory drug associated with anti-tumorigenic and pro-apoptotic

192 sitivity-the increased susceptibility to one drug associated with evolved resistance to a different d

193 ated the metabolic footprint of metformin, a drug associated with improved post-MI LV function in exp

194 When a drug associated with torsades de pointes was prescribed

195 primary human hepatocytes were treated with drugs associated with a high incidence of DILI (flucloxa

196 of the interactions, as well as diseases and drugs associated with a single nucleotide polymorphism o

197 ug Administration (FDA)-approved peptidergic drugs associated with allergic-type injection-site react

198 agogues, including inflammatory peptides and drugs associated with allergic-type reactions.

199 lation coefficient > 0.3) with the number of drugs associated with an indication and moderately corre

200 Many drugs associated with autoimmunity are susceptible to ox

201 We found 14, 10, 7% of all drugs associated with colon, prostate, and breast cancer

202 sed AD risk, and use of cholesterol-lowering drugs associated with decreased risk.

203 Drugs associated with high rates of positive rechallenge

204 al corticosteroids alone, are oral antiviral drugs associated with improved outcomes when combined wi

205 Drugs associated with increased risk of pulmonary emboli

206 ve affective biases following treatment with drugs associated with inducing negative affective states

207 ranous nephropathy (MN) with the most common drugs associated with MN being nonsteroidal anti-inflamm

208 All opioid drugs associated with mortality; most associated with wo

209 Overall, we identify 62 drugs associated with myocarditis, 41 of which are categ

210 Drugs associated with reduced mortality were then valida

211 Are antiepileptic drugs associated with reduced pain intensity in patients

212 Drugs associated with reports of angle-closure glaucoma

213 d MRGPRX2 are targets of many small-molecule drugs associated with systemic pseudo-allergic, or anaph

214 rt the notion that many of the antipsychotic drugs associated with the development of movement disord

215 990s, underscoring the advantages of aptamer drugs associated with their unique binding properties.

216 t Reporting System database was searched for drugs associated with thrombocytopenia by use of data mi

217 arrhythmic drugs, especially amiodarone, and drugs associated with torsade de pointes may have contri

218 idine and clopidogrel, are the 2 most common drugs associated with TTP in databases maintained by the

219 1%) had taken quinine, and 7 had taken other drugs associated with TTP-HUS.

220 Opioids are the most common drugs associated with unintentional drug overdose.

221 with 27 also associated with VA or SD) and 9 drugs associated with VA without diLQT.

222 also found starchy, musky, sweet, and soapy drugs associated with versatility.